Business Context and Reporting Period
CalciMedica, Inc. (Nasdaq: CALC), a Delaware corporation, filed this Form 8-K on February 28, 2025, to report the entry into a material definitive agreement. The company is an emerging growth company focused on clinical trials for its product candidates.
Key Financial Metrics and Transaction Details
The filing details a new debt facility rather than historical financial performance metrics such as revenue or cash flow.
- Total Loan Capacity: Up to $32,500,000 in aggregate principal.
- Initial Funding (Tranche 1): $10,000,000 funded on the Closing Date (February 28, 2025).
- Future Funding (Tranche 2): Up to $7,500,000 available between September 1, 2025, and March 31, 2026, subject to clinical milestones.
- Future Funding (Tranche 3): Up to $15,000,000 available between October 1, 2025, and March 31, 2026, subject to milestones and mutual agreement.
- Interest Rate: The greater of (a) 5.00% plus the prime rate or (b) 12.75% annually.
- Repayment Terms: Interest-only payments until the 18-month anniversary of the Closing Date, with a potential 6-month extension upon milestone achievement. Maturity date is September 1, 2028.
- Final Payment: 3.75% of the aggregate principal amount funded.
- Collateral: Secured by a lien on all company assets, including intellectual property.
- Warrant Issuance: A warrant to purchase 641,163 shares at an exercise price of $2.32 per share, exercisable until February 28, 2030.
- Conversion Rights: Lender may convert up to $2,000,000 of principal into common stock at 120% of the Stock Purchase Price.
Material Changes and Covenants
This filing represents a significant change in the company's capital structure, introducing a new secured debt obligation. The Loan Agreement does not contain minimum cash requirements or other financial covenants. However, it includes customary affirmative and negative covenants and events of default, including insolvency, failure to pay, material adverse effects, and unsatisfied judgments exceeding $250,000.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on future revenue projections. The primary risks associated with this transaction include:
- Milestone Dependency: Access to $22.5 million of the total loan facility is contingent upon achieving specific clinical trial milestones.
- Dilution Risk: The issuance of warrants and the potential conversion of loan principal into equity may dilute existing shareholders.
- Prepayment Penalties: Prepayment premiums range from 3.00% (within first year) to 1.00% (after second year).
- Default Consequences: An event of default allows the lender to demand immediate repayment of all principal and interest and exercise remedies against company assets.
Investor Verification Checklist
- Verify the specific clinical trial milestones required to unlock Tranche 2 and Tranche 3 funding.
- Review the full text of the Loan and Security Agreement (Exhibit 10.1) for detailed affirmative and negative covenants.
- Assess the impact of the warrant issuance (641,163 shares) and potential conversion on current share count and dilution.
- Confirm the company's current cash position to ensure ability to service interest-only payments until the 18-month anniversary.
- Monitor the company's progress on ongoing clinical trials to gauge the likelihood of full loan funding.